These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21591585)

  • 1. Flecainide.
    Ector H
    Acta Cardiol; 2011 Apr; 66(2):247-8. PubMed ID: 21591585
    [No Abstract]   [Full Text] [Related]  

  • 2. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
    Freemantle N; Lafuente-Lafuente C; Mitchell S; Eckert L; Reynolds M
    Europace; 2011 Mar; 13(3):329-45. PubMed ID: 21227948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interstitial pneumopathy due to flecainide].
    Haas M; Pérault MC; Bonnefoy P; Rodeau F; Caron F
    Presse Med; 2001 Jun 16-23; 30(21):1062. PubMed ID: 11471279
    [No Abstract]   [Full Text] [Related]  

  • 4. Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
    Piccini JP; Kong DF
    Europace; 2011 Mar; 13(3):295-6. PubMed ID: 21345924
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of flecainide-induced hyponatremia.
    Ahmed M; Sra J; Akhtar M; Mortada ME
    J Cardiovasc Electrophysiol; 2009 Oct; 20(10):1170-2. PubMed ID: 19298558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.
    Aliot E; Capucci A; Crijns HJ; Goette A; Tamargo J
    Europace; 2011 Feb; 13(2):161-73. PubMed ID: 21138930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confused and Too Long: Neurotoxicity and Cardiac Toxicity of Flecainide.
    Tsai TF; Garcia RT; Bui JQ; Thinda A; Amsterdam EA
    Crit Pathw Cardiol; 2017 Mar; 16(1):42-45. PubMed ID: 28195943
    [No Abstract]   [Full Text] [Related]  

  • 8. [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder].
    Rienstra M; Wiesfeld AC; van Veldhuisen DJ; van Gelder IC
    Ned Tijdschr Geneeskd; 2006 May; 150(18):1027-31. PubMed ID: 16715868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation.
    Nagai S; Takeishi Y; Kubota I
    Cardiovasc Drugs Ther; 2003 Jan; 17(1):95-7. PubMed ID: 12916520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does a Brugada pattern ECG precipitated by excessive-dose flecainide provide a diagnosis of a Brugada syndrome patient and/or contraindicate its use? A case study.
    Reiffel JA
    Circ Arrhythm Electrophysiol; 2011 Aug; 4(4):e47-51. PubMed ID: 21846883
    [No Abstract]   [Full Text] [Related]  

  • 11. Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate.
    Fornieles-Pérez H; Montoya-García M; Levine PA; Sanz O
    Pacing Clin Electrophysiol; 2002 May; 25(5):871-2. PubMed ID: 12049386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation.
    Kühlkamp V; Schmid F; Risler T; Seipel L
    Int J Cardiol; 1991 Apr; 31(1):65-9. PubMed ID: 1906432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group.
    Naccarelli GV; Dorian P; Hohnloser SH; Coumel P
    Am J Cardiol; 1996 Jan; 77(3):53A-59A. PubMed ID: 8607392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation].
    Martínez-Sellés M; Castillo I; Montenegro P; Martín ML; Almendral J; Sanjurjo M
    Rev Esp Cardiol; 2005 Jun; 58(6):745-8. PubMed ID: 15970126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 2-year survey of treatment of acute atrial fibrillation in an ED.
    Hirschl MM; Wollmann C; Globits S
    Am J Emerg Med; 2011 Jun; 29(5):534-40. PubMed ID: 20825828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the efficacy and safety of dronedarone and flecainide as maintenance antiarrhythmic therapy for sinus rhythm in atrial fibrillation].
    Sánchez Soriano RM; Chamorro Fernández CI; Ruiz Nodar JM; Chamorro Fernández AJ; Grau Jornet G; Nuñez Villota J
    Arch Cardiol Mex; 2018; 88(3):204-211. PubMed ID: 28864237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Termination of atrial fibrillation by flecainide: mechanistic insights from spectral analysis.
    Hunter RJ; Schilling RJ
    Europace; 2010 Apr; 12(4):453-4. PubMed ID: 20167613
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of patients with acute atrial fibrillation in the ED.
    Conti A; Del Taglia B; Mariannini Y; Pepe G; Vanni S; Grifoni S; Abbate R; Michelucci A; Padeletti L; Gensini GF
    Am J Emerg Med; 2010 Oct; 28(8):903-10. PubMed ID: 20825922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M; Cullen MT; Casadei G
    Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.
    Camm AJ; Savelieva I
    BMJ; 2007 Mar; 334(7594):637. PubMed ID: 17379911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.